|
|
|
|
R&D Medicines > Medical Marijuana
|
We have sponsored and supported research with marijuana since our inception. MAPS is the only organization that is attempting to resolve the controversy over medical marijuana via the United States Food and Drug Administration (FDA) research route.
MAPS’ goal is to initiate and fund a serious drug development research program aimed at proving to the satisfaction of FDA that marijuana is safe and efficacious for specific medical uses and should become a legal, FDA-approved prescription medicine. While we have recently been hindered by United States government agencies in our attempts to conduct clinical trials using medical marijuana - we will ultimately achieve our goal.
On this page we provide information about research that we have sponsored or conducted, and our legal challenges with the different agencies that have obstructed us. |
|
Summary of the Process to Develop Marijuana into a Prescription Medicine
MAPS Planned Marijuana Production Facility and Legal Challenges |
MAPS, in association with Prof. Lyle Craker, Director, Medicinal Plant Program, University of Massachusetts Amherst, Department of Plant and Soil Sciences, has been seeking DEA permission to establish a medical marijuana production facility to grow high-potency marijuana for FDA-approved research.
|
The UMass Amherst Medical Marijuana Production Facility Project
Timeline of Legal Process for License to Grow Marijuana for Research
DEA Lawsuit Supporting Prof. Craker’s Proposed UMass/Amherst Marijuana Production Facility
MAPS/CaNORML Vaporizer and Water-Pipe Studies |
MAPS, in conjunction with California NORML, has been working since 1993 to sponsor scientific research into the effects of vaporizers and water-pipes in filtering the constituents of inhaled marijuana. Our goal was to determine if water-pipes or vaporizers could reduce the health risks of smoking marijuana. From 1993 to 2002, we sponsored research at DEA-licensed laboratories testing the content of combusted and vaporized marijuana for cannabinoid particulate and carbon monoxide levels. We have been unsuccessfully attempting to purchase marijuana from the National Institute on Drug Abuse for more research with vaporized marijuana since June 2003.
|
MAPS Planned Vaporizer Research
MAPS’ Two Prerequisites for FDA Drug Development Research of Marijuana
Water-pipe and Vaporizer Articles from MAPS Bulletin 1994-2004
Results from MAPS Studies of Vaporizers and Water-Pipes
Timeline of Vaporizer Research News
Links to Vaporizer Distributors
Orphan Drug Designation for Smoked Marijuana in the Treatment of HIV-Associated Wasting Syndrome |
On May 25, 1999, MAPS successfully secured Orphan Drug Designation for Marijuana in the treatment of AIDS wasting syndrome. Since it is not possible to obtain a patent on marijuana for use as a prescription medicine, an Orphan Drug Designation makes marijuana available for research and development into a prescription medicine. The Orphan Drug Designation program was developed by congress to facilitate the development of rare drugs. In the years since MAPS obtained permission to study this treatment, the advent of protease inhibitors has largely eliminated AIDS wasting syndrome in the US. As a result, we have not pursued this research. |
History of MAPS Orphan Drug Designation Campaign
MAPS/Marijuana Related News and Timeline |
MAPS has supported marijuana research since 1986. Below are links to past projects, peripheral organizations’ research, and a timeline of news and events. |
MAPS/Marijuana Related News and Timeline
Past MAPS Studies
Additional Resources
Marijuana in the News Media |
The following is a collection of MAPS and Marijuana research related articles. |
Marijuana Related News
|
|
|
|
|
|